Primer Capital
Primer Capital is a venture capital firm based in Moscow, Russia, specializing in early-stage investments in the pharmaceutical and biotechnology sectors. Established in 2015, the firm focuses on promising projects in areas such as oncology, cardiology, rheumatology, and medical devices, among others. Primer Capital typically invests between $0.2 million and $0.5 million and also considers co-investments, collaborating with various stakeholders, including other venture capital funds, business angels, and government agencies interested in the biopharmaceutical industry. The firm benefits from a qualified team and a Scientific Advisory Board made up of experts in medical and biopharmaceutical fields, which aids in the careful selection of projects for its portfolio. Primer Capital's extensive experience and knowledge of the industry ecosystem enhance the prospects for its portfolio companies, supporting them in establishing effective partnerships and facilitating fundraising throughout their development.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
14 past transactions
Nelo
Series A in 2021
Nelo is a Mexico City-based company that specializes in developing a mobile application for financial transactions. Founded on April 8, 2019, Nelo offers a digital payment management platform that enables users to track their financial transactions effectively. The platform allows individuals to send and request money while providing a free virtual card with no charges for account opening. This functionality facilitates real-time payment and balance tracking, empowering users to manage their funds in an affordable and secure manner.
MatriSys Bioscience
Venture Round in 2021
MatriSys Bioscience is a clinical-stage biopharmaceutical company focused on developing microbiome therapies for dermatology and skin care markets worldwide. Its lead product, MSB-01, is a topical antimicrobial live bio therapeutic designed to replace deficient bacteria on the skin of atopic dermatitis patients, promoting host defense. The company also offers cosmetic ingredients derived from its proprietary bacterial strains, formulated into cream or gel forms to address various skin concerns such as scaling, flaking, redness, and signs of aging.
Botkin.AI
Series B in 2020
Botkin.AI is a Moscow-based company established in 2015. It develops an AI-driven platform for medical image processing and analysis, focusing on tumor risk assessment using deep learning algorithms. The platform enhances radiologists' diagnostic capabilities and accelerates patient data processing without compromising conclusion quality.
Athira Pharma
Convertible Note in 2020
Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.
MatriSys Bioscience
Seed Round in 2018
MatriSys Bioscience is a clinical-stage biopharmaceutical company focused on developing microbiome therapies for dermatology and skin care markets worldwide. Its lead product, MSB-01, is a topical antimicrobial live bio therapeutic designed to replace deficient bacteria on the skin of atopic dermatitis patients, promoting host defense. The company also offers cosmetic ingredients derived from its proprietary bacterial strains, formulated into cream or gel forms to address various skin concerns such as scaling, flaking, redness, and signs of aging.
Acticor Biotech
Series A in 2018
Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.
GemoPharm
Venture Round in 2017
GemoPharm is a biotechnology company focused on developing innovative therapies for challenging medical conditions. Its lead asset is a monoclonal antibody targeting CD71 within the tumor microenvironment, designed to minimize toxicities commonly associated with traditional therapies. The company has successfully generated in vivo proof-of-concept data that demonstrate substantial efficacy and validate the mechanism of action for its lead candidate. Additionally, pilot toxicology studies have been completed without any signs of significant toxicity. GemoPharm aims to address the significant unmet medical needs for effective treatments of relapsed or refractory primary and secondary central nervous system lymphomas and intraocular lymphomas. The company’s research also extends to developing humanized antibodies with strong antitumor activity and minimal toxicity, leveraging cellular and biomolecular processes to enhance patient outcomes in the fight against infections.
MT Medicals
Venture Round in 2017
MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrate high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports the individualization of such treatment.
MT-Medicals is based in Hefei City, Anhui Province, China.
Bendit
Series A in 2017
Bendit is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology. This technology provides enhanced steering capabilities in both micro diameter and conventional catheter wires and tubes. The company focuses on creating microcatheter devices that enable precise navigation within the body, allowing healthcare professionals to access targeted sites with minimal tools and reduced risks. Bendit's products are designed to improve the success rates of medical procedures by offering peripheral and visceral microcatheters that can be shaped and directed as needed. The company is a joint venture formed by three experienced groups in production, quality and regulation, and medical development, bringing together expertise to advance catheter technology.
Botkin.AI
Seed Round in 2017
Botkin.AI is a Moscow-based company established in 2015. It develops an AI-driven platform for medical image processing and analysis, focusing on tumor risk assessment using deep learning algorithms. The platform enhances radiologists' diagnostic capabilities and accelerates patient data processing without compromising conclusion quality.
Data MATRIX
Series A in 2016
Founded in 2014, Data MATRIX specializes in data management services for clinical trials. It offers a cloud-based EDC platform, Matrix EDC, supporting electronic, paper-based, and hybrid studies. The company also provides patient randomization services via Matrix IWRS, clinical trial management through Matrix CTMS, and drug dispensing and supply management.
MiNDERA Corporation
Seed Round in 2016
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.
FK Laboratoriz
Seed Round in 2016
FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.
Solo
Seed Round in 2016
Solo is a service for personalized anticancer therapy selection.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.